Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection

Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The SPRi assay measures the antibody isotype levels and the strength of binding to the RBD...

Descripción completa

Detalles Bibliográficos
Autores principales: Schasfoort, Richard B.M., van Weperen, Jos, van Amsterdam, Margot, Parisot, Judicaël, Hendriks, Jan, Koerselman, Michelle, Karperien, Marcel, Mentink, Anouk, Bennink, Martin, Krabbe, Hans, Terstappen, Leon WMM., Mulder, A.H. Leontine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962981/
https://www.ncbi.nlm.nih.gov/pubmed/33799060
http://dx.doi.org/10.1016/j.bios.2021.113165
_version_ 1783665554927648768
author Schasfoort, Richard B.M.
van Weperen, Jos
van Amsterdam, Margot
Parisot, Judicaël
Hendriks, Jan
Koerselman, Michelle
Karperien, Marcel
Mentink, Anouk
Bennink, Martin
Krabbe, Hans
Terstappen, Leon WMM.
Mulder, A.H. Leontine
author_facet Schasfoort, Richard B.M.
van Weperen, Jos
van Amsterdam, Margot
Parisot, Judicaël
Hendriks, Jan
Koerselman, Michelle
Karperien, Marcel
Mentink, Anouk
Bennink, Martin
Krabbe, Hans
Terstappen, Leon WMM.
Mulder, A.H. Leontine
author_sort Schasfoort, Richard B.M.
collection PubMed
description Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The SPRi assay measures the antibody isotype levels and the strength of binding to the RBD of ultimate 384 patient samples in one run. It turns out that during the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels go down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immunoglobulins SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19 and this new method can furthermore be applied for the assessment of the quality of the immune reaction of healthy individuals to SARS-CoV-2 in vaccination programs.
format Online
Article
Text
id pubmed-7962981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-79629812021-03-17 Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection Schasfoort, Richard B.M. van Weperen, Jos van Amsterdam, Margot Parisot, Judicaël Hendriks, Jan Koerselman, Michelle Karperien, Marcel Mentink, Anouk Bennink, Martin Krabbe, Hans Terstappen, Leon WMM. Mulder, A.H. Leontine Biosens Bioelectron Article Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The SPRi assay measures the antibody isotype levels and the strength of binding to the RBD of ultimate 384 patient samples in one run. It turns out that during the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels go down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immunoglobulins SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19 and this new method can furthermore be applied for the assessment of the quality of the immune reaction of healthy individuals to SARS-CoV-2 in vaccination programs. The Author(s). Published by Elsevier B.V. 2021-07-01 2021-03-16 /pmc/articles/PMC7962981/ /pubmed/33799060 http://dx.doi.org/10.1016/j.bios.2021.113165 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Schasfoort, Richard B.M.
van Weperen, Jos
van Amsterdam, Margot
Parisot, Judicaël
Hendriks, Jan
Koerselman, Michelle
Karperien, Marcel
Mentink, Anouk
Bennink, Martin
Krabbe, Hans
Terstappen, Leon WMM.
Mulder, A.H. Leontine
Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title_full Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title_fullStr Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title_full_unstemmed Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title_short Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection
title_sort presence and strength of binding of igm, igg and iga antibodies against sars-cov-2 during covid-19 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962981/
https://www.ncbi.nlm.nih.gov/pubmed/33799060
http://dx.doi.org/10.1016/j.bios.2021.113165
work_keys_str_mv AT schasfoortrichardbm presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT vanweperenjos presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT vanamsterdammargot presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT parisotjudicael presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT hendriksjan presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT koerselmanmichelle presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT karperienmarcel presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT mentinkanouk presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT benninkmartin presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT krabbehans presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT terstappenleonwmm presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection
AT mulderahleontine presenceandstrengthofbindingofigmiggandigaantibodiesagainstsarscov2duringcovid19infection

Ejemplares similares